{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T08:35:30Z","timestamp":1764232530590,"version":"3.46.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,27]]},"DOI":"10.7759\/cureus.97906","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T08:31:05Z","timestamp":1764232265000},"source":"Crossref","is-referenced-by-count":0,"title":["Caplacizumab in Lupus-Associated Thrombotic Thrombocytopenic Purpura (TTP): Navigating Autoimmunity and Microangiopathy"],"prefix":"10.7759","author":[{"given":"Arathi","family":"Kulkarni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiera","family":"Vaughn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Curtis","family":"Lacy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamin","family":"Sultani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandana","family":"Keshavamurthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2018.06.010","article-title":"Thrombotic microangiopathies with rheumatologic involvement","volume":"44","author":"Babar F","year":"2018","unstructured":"Babar F, Cohen SD. Thrombotic microangiopathies with rheumatologic involvement. Rheum Dis Clin North Am. 2018, 44:635-49. 10.1016\/j.rdc.2018.06.010","journal-title":"Rheum Dis Clin North Am"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.3807","article-title":"Immune thrombotic thrombocytopenic purpura: a review","volume":"334","author":"Pishko AM","year":"2025","unstructured":"Pishko AM, Li A, Cuker A. Immune thrombotic thrombocytopenic purpura: a review. JAMA. 2025, 334:517-29. 10.1001\/jama.2025.3807","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully M","year":"2019","unstructured":"Scully M, Cataland SR, Peyvandi F, et al.. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019, 380:335-46. 10.1056\/NEJMoa1806311","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018019596","article-title":"Complement-mediated thrombotic microangiopathy associated with lupus nephritis","volume":"2","author":"Park MH","year":"2018","unstructured":"Park MH, Caselman N, Ulmer S, Weitz IC. Complement-mediated thrombotic microangiopathy associated with lupus nephritis. Blood Adv. 2018, 2:2090-4. 10.1182\/bloodadvances.2018019596","journal-title":"Blood Adv"},{"key":"ref5","article-title":"Diagnosis of atypical hemolytic uremic syndrome and response to eculizumab therapy","volume":"73","author":"Nguyen MH","year":"2014","unstructured":"Nguyen MH, Mathew JJ, Denunzio TM, Carmichael MG. Diagnosis of atypical hemolytic uremic syndrome and response to eculizumab therapy. Hawaii J Med Public Health. 2014, 73:22-4.","journal-title":"Hawaii J Med Public Health"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5001535","article-title":"The molecular biology of thrombotic microangiopathy","volume":"70","author":"Tsai HM","year":"2006","unstructured":"Tsai HM. The molecular biology of thrombotic microangiopathy. Kidney Int. 2006, 70:16-23. 10.1038\/sj.ki.5001535","journal-title":"Kidney Int"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12160","article-title":"Thrombotic thrombocytopenic purpura: toward targeted therapy and precision medicine","volume":"3","author":"Coppo P","year":"2019","unstructured":"Coppo P, Cuker A, George JN. Thrombotic thrombocytopenic purpura: toward targeted therapy and precision medicine. Res Pract Thromb Haemost. 2019, 3:26-37. 10.1002\/rth2.12160","journal-title":"Res Pract Thromb Haemost"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4103\/0972-5229.43682","article-title":"Thrombotic thrombocytopenic purpura and systemic lupus erythematosus: successful management of a rare presentation","volume":"12","author":"George P","year":"2008","unstructured":"George P, Das J, Pawar B, Kakkar N. Thrombotic thrombocytopenic purpura and systemic lupus erythematosus: successful management of a rare presentation. Indian J Crit Care Med. 2008, 12:128-31. 10.4103\/0972-5229.43682","journal-title":"Indian J Crit Care Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.607211","article-title":"Factor H autoantibodies and complement-mediated diseases","volume":"11","author":"Zhang Y","year":"2020","unstructured":"Zhang Y, Ghiringhelli Borsa N, Shao D, et al.. Factor H autoantibodies and complement-mediated diseases. Front Immunol. 2020, 11:607211. 10.3389\/fimmu.2020.607211","journal-title":"Front Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.119.13714","article-title":"Diagnostic and risk factors for complement defects in hypertensive emergency and thrombotic microangiopathy","volume":"75","author":"Timmermans SA","year":"2020","unstructured":"Timmermans SA, W\u00e9rion A, Damoiseaux JG, Morelle J, Reutelingsperger CP, van Paassen P. Diagnostic and risk factors for complement defects in hypertensive emergency and thrombotic microangiopathy. Hypertension. 2020, 75:422-30. 10.1161\/HYPERTENSIONAHA.119.13714","journal-title":"Hypertension"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2025.06.002","article-title":"2025 focused update of the 2020 ISTH guidelines for management of thrombotic thrombocytopenic purpura","volume":"23","author":"Zheng XL","year":"2025","unstructured":"Zheng XL, Al-Housni Z, Cataland SR, et al.. 2025 focused update of the 2020 ISTH guidelines for management of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2025, 23:3711-32. 10.1016\/j.jtha.2025.06.002","journal-title":"J Thromb Haemost"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15954","article-title":"Diagnostic accuracy of the PLASMIC score in patients with suspected thrombotic thrombocytopenic purpura: a systematic review and meta-analysis","volume":"60","author":"Paydary K","year":"2020","unstructured":"Paydary K, Banwell E, Tong J, Chen Y, Cuker A. Diagnostic accuracy of the PLASMIC score in patients with suspected thrombotic thrombocytopenic purpura: a systematic review and meta-analysis. Transfusion. 2020, 60:2047-57. 10.1111\/trf.15954","journal-title":"Transfusion"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2314793","article-title":"Recombinant ADAMTS13 in congenital thrombotic thrombocytopenic purpura","volume":"390","author":"Scully M","year":"2024","unstructured":"Scully M, Antun A, Cataland SR, et al.. Recombinant ADAMTS13 in congenital thrombotic thrombocytopenic purpura. N Engl J Med. 2024, 390:1584-96. 10.1056\/NEJMoa2314793","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura","volume":"325","author":"Rock GA","year":"1991","unstructured":"Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med. 1991, 325:393-7. 10.1056\/NEJM199108083250604","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15721","article-title":"Deaths and complications associated with the management of acute immune thrombotic thrombocytopenic purpura","volume":"60","author":"Colling M","year":"2020","unstructured":"Colling M, Sun L, Upadhyay V, et al.. Deaths and complications associated with the management of acute immune thrombotic thrombocytopenic purpura. Transfusion. 2020, 60:841-6. 10.1111\/trf.15721","journal-title":"Transfusion"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017009308","article-title":"Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune-mediated thrombotic thrombocytopenic purpura","volume":"1","author":"Cataland SR","year":"2017","unstructured":"Cataland SR, Kourlas PJ, Yang S, et al.. Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune-mediated thrombotic thrombocytopenic purpura. Blood Adv. 2017, 1:2075-82. 10.1182\/bloodadvances.2017009308","journal-title":"Blood Adv"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-00092-2","article-title":"B cell depletion therapies in autoimmune disease: advances and mechanistic insights","volume":"20","author":"Lee DS","year":"2021","unstructured":"Lee DS, Rojas OL, Gommerman JL. B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat Rev Drug Discov. 2021, 20:179-99. 10.1038\/s41573-020-00092-2","journal-title":"Nat Rev Drug Discov"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/1076029618825309","article-title":"Comparison of the long-term remission of rituximab and conventional treatment for acquired thrombotic thrombocytopenic purpura: a systematic review and meta-analysis","volume":"25","author":"Owattanapanich W","year":"2019","unstructured":"Owattanapanich W, Wongprasert C, Rotchanapanya W, Owattanapanich N, Ruchutrakool T. Comparison of the long-term remission of rituximab and conventional treatment for acquired thrombotic thrombocytopenic purpura: a systematic review and meta-analysis. Clin Appl Thromb Hemost. 2019, 25:10.1177\/1076029618825309","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.10.030","article-title":"The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders","volume":"127","author":"Ballow M","year":"2011","unstructured":"Ballow M. The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J Allergy Clin Immunol. 2011, 127:315-23. 10.1016\/j.jaci.2010.10.030","journal-title":"J Allergy Clin Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/412536-caplacizumab-in-lupus-associated-thrombotic-thrombocytopenic-purpura-ttp-navigating-autoimmunity-and-microangiopathy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T08:31:06Z","timestamp":1764232266000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/412536-caplacizumab-in-lupus-associated-thrombotic-thrombocytopenic-purpura-ttp-navigating-autoimmunity-and-microangiopathy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.97906","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,27]]}}}